Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data from RECVASA Registries)
Open Access
- 30 December 2020
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 16 (6), 888-898
- https://doi.org/10.20996/1819-6446-2020-12-01
Abstract
Aim. To study comorbidity, drug therapy and outcomes in patients with atrial fibrillation (AF) included in the outpatient and hospital RECVASA registries. Material and methods. Patients with AF (n=3169; age 70.9±10.7 years; 43.1% of men) in whom comorbidity, drug therapy, short-term and longterm outcomes (follow-up period from 2 to 6 years) were included in hospital registers RECVASA AF (Moscow, Kursk, Tula), as well as outpatient registers RECVASA (Ryazan) and RECVASA AF-Yaroslavl. Results. Outpatient registries (n=934), as compared to hospital registries (n=2235), had a higher average age of patients (73.4±10.9 vs 69.9±10.5; p2DS2-VASc 4.65±1.58 vs 4.15±1.71; pConclusion. The majority of patients with AF registries in 5 regions of Russia had a combination of three or more cardiovascular diseases (73.9%), as well as chronic non-cardiac diseases (68.8%). The frequency of proper cardiovascular pharmacotherapy was insufficient (68.6%), especially at the outpatient stage (55.6%). Over the observation period (2-6 years), the average mortality per year was 10.3%, but at the same time it differed significantly in the regions (from 3.7% in Moscow to 9.7-12.5% in Yaroslavl, Ryazan and Kursk). Cardiovascular causes of deaths occurred in 62%. A higher risk of death (1.5-2.7 times) was associated with a history of stroke and MI, diabetes mellitus, COPD, heart rate>80 bpm, systolic blood pressure <110 mm Hg, decreased hemoglobin level. However, the risk of death decreased by 1.2-2.4 times in cases of prescription of anticoagulants, ACE inhibitors / ARBs, beta-blockers and statins. The risk of ACVA and MI was the highest in the presence of the history of this event (2.7 and 2.6 times, respectively). Anticoagulant prescription was significantly associated with a reduced risk of stroke in women.Keywords
This publication has 25 references indexed in Scilit:
- Worldwide Epidemiology of Atrial FibrillationCirculation, 2014
- Causes of Death and Influencing Factors in Patients With Atrial FibrillationCirculation, 2013
- Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)EP Europace, 2013
- Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention TrialAmerican Heart Journal, 2013
- Frequency, Patient Characteristics, Treatment Strategies, and Resource Usage of Atrial Fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] Study)The American Journal of Cardiology, 2013
- Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registryClinical Research in Cardiology, 2011
- Multimorbidity and risk among patients with established cardiovascular disease: a cohort studyBritish Journal of General Practice, 2008
- Coronary Ischemic Events after First Atrial Fibrillation: Risk and SurvivalThe American Journal of Medicine, 2007
- Atrial fibrillation management: a prospective survey in ESC Member CountriesEuropean Heart Journal, 2005
- Acute Stroke With Atrial FibrillationStroke, 1996